Trade Genfit SA - GNFTfr CFD
Add to favourite- Summary
- Historical Data
Spread | 0.10 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.021418% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | -0.000804% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | EUR | ||||||||
Margin | 5.00% | ||||||||
Stock exchange | France | ||||||||
Commission on trade | 0% |
Prev. Close | 3.86 |
Open | 3.84 |
1-Year Change | 20.38% |
Day's Range | 3.72 - 3.84 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Sep 6, 2024 | 3.73 | -0.10 | -2.61% | 3.83 | 3.86 | 3.67 |
Sep 5, 2024 | 3.86 | 0.08 | 2.12% | 3.78 | 3.91 | 3.78 |
Sep 4, 2024 | 3.74 | 0.15 | 4.18% | 3.59 | 3.83 | 3.58 |
Sep 3, 2024 | 3.60 | -0.04 | -1.10% | 3.64 | 3.74 | 3.60 |
Sep 2, 2024 | 3.64 | -0.19 | -4.96% | 3.83 | 3.88 | 3.64 |
Aug 30, 2024 | 3.84 | -0.05 | -1.29% | 3.89 | 3.96 | 3.82 |
Aug 29, 2024 | 3.91 | 0.11 | 2.89% | 3.80 | 3.92 | 3.74 |
Aug 28, 2024 | 3.77 | -0.05 | -1.31% | 3.82 | 3.90 | 3.76 |
Aug 27, 2024 | 3.79 | -0.09 | -2.32% | 3.88 | 3.95 | 3.79 |
Aug 26, 2024 | 3.89 | 0.02 | 0.52% | 3.87 | 3.93 | 3.86 |
Aug 23, 2024 | 3.84 | -0.01 | -0.26% | 3.85 | 3.94 | 3.82 |
Aug 22, 2024 | 3.79 | -0.19 | -4.77% | 3.98 | 3.98 | 3.79 |
Aug 21, 2024 | 3.96 | 0.17 | 4.49% | 3.79 | 4.01 | 3.79 |
Aug 20, 2024 | 3.81 | 0.00 | 0.00% | 3.81 | 3.92 | 3.81 |
Aug 19, 2024 | 3.84 | 0.04 | 1.05% | 3.80 | 3.90 | 3.78 |
Aug 16, 2024 | 3.83 | 0.07 | 1.86% | 3.76 | 3.92 | 3.76 |
Aug 15, 2024 | 3.75 | 0.04 | 1.08% | 3.71 | 3.80 | 3.68 |
Aug 14, 2024 | 3.76 | 0.08 | 2.17% | 3.68 | 3.85 | 3.68 |
Aug 13, 2024 | 3.66 | -0.02 | -0.54% | 3.68 | 3.74 | 3.64 |
Aug 12, 2024 | 3.63 | -0.06 | -1.63% | 3.69 | 3.74 | 3.63 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Genfit Company profile
About Genfit SA
Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The Company targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.
Financial summary
BRIEF: For the six months ended 30 June 2021, Genfit SA revenues decreased 42% to EUR3.4M. Net income totaled EUR9.1M vs. loss of EUR53M. Revenues reflect Public Financing of research expenditure decrease of 38% to EUR3.2M, Other Operating Income decrease of 66% to EUR174K, Revenue decrease of 91% to EUR11K. Net Income reflects R&D Subcontractors decrease of 38% to EUR15M (expense).
Equity composition
01/2014, Rights Issue, 1 new share for every 33 shares held @ EUR6.98 (Factor: 1.00937).10/2016, Rights Issue, 1 new share for every 9 shares held @ EUR14.3 (Factor: 1.09242).
Industry: | Biotechnology & Medical Research (NEC) |
Parc Eurasanté 885 avenue Eugène Avinée
LOOS
HAUTS-DE-FRANCE 59120
FR
News
![](https://img.capital.com/imgs/articles/192x130x1/1350x880_-HP-_Newsquawk-light.png)
Introducing Newsquawk: your new in-platform newsfeed
We are very excited to announce the launch of Newsquawk in the Capital.com platform and app. This new newsfeed is designed to help you get ahead with real-time headlines, personalised stories and in-depth reports – all available directly in the platform and app, where you need them.
14:09, 20 August 2024![](https://img.capital.com/imgs/articles/192x130x1/Gold_10.jpg)
Jackson Hole Preview: All eyes on Powell and Gold
The key focus this week will be on Jerome Powell and any insight he may give into the future of monetary policy.
15:24, 19 August 2024![](https://img.capital.com/imgs/articles/192x130x1/USUK.jpg)
All eyes on inflation: US and UK CPI take centre stage
Just over a month has gone by since the latest CPI data was released in the US and so much has happened since.
14:41, 13 August 2024![](https://img.capital.com/imgs/articles/192x130x1/European-stocks_0.jpg)
European stocks face resistance in their attempt to recover
European stocks struggle to recover as the tech sector faces continued downside pressure in Asia.
13:56, 9 August 2024![](https://img.capital.com/imgs/articles/192x130x1/Global-selloff_0.jpg)
Global selloff continues on US economy fears
Thursday’s rise in jobless claims led to a market meltdown in the US stock market as investors became concerned that the Federal Reserve made the wrong decision by keeping rates unchanged on Wednesday.
14:40, 5 August 2024![](https://img.capital.com/imgs/articles/192x130x1/Graphiccs-1-.png)
FOMC PREVIEW
Markets believe the Federal reserve will continue to leave their monetary policy unchanged at the meeting next week.
14:09, 1 August 2024![](https://img.capital.com/imgs/articles/192x130x1/Risk-Management-in-Trading.png)
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024People also watch
Still looking for a broker you can trust?
Join the 640,000+ traders worldwide that chose to trade with Capital.com